A Study to Determine the Relative Bioavailability of a Tablet Formulation of GDC-0941 and the Effect of Ketoconazole on the Pharmacokinetics of the GDC-0941 Tablet

Launched by GENENTECH, INC. · Nov 10, 2010

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • Medically healthy as determined by the absence of clinically significant findings in the physical examination, medical history, vital sign measurements, clinical laboratory tests, or 12-lead electrocardiograms (ECGs)
• • For female subjects: postmenopausal and without recent history of menorrhea, surgically sterile or using an effective method of contraception such as oral or transdermal contraceptives, double-barrier contraception, intrauterine device, depot progesterone, or implanted contraceptive devices, from Day -1 until 45 days after study drug completion/discharge; female subjects must have a negative pregnancy test at Screening and on Day -1
• • For male subjects: sterile or a sterile sexual partner, or agreement to use 2 forms of medically acceptable methods of contraception, one of which is a barrier, and agreement not to donate sperm from Screening throughout the study period and for at least 3 months after the last dose of study drug.
• • Exclusion Criteria
• • History of clinical manifestations of significant metabolic (including type 1 and 2 diabetes), hepatic, renal, hematological, pulmonary, cardiovascular, endocrine, gastrointestinal (including gastric or duodenal ulcers), urological, neurological, or psychiatric disease, or cancer
• • History of inflammatory arthritis
• • History of symptomatic hypotension
• • History of severe physical injury, direct impact trauma, or neurological trauma within a specified timeframe prior to initiation of study treatment
• • History of seizure disorders
• • History of bipolar or major depressive disorder
• • History of stomach or intestinal surgery or resection (except appendectomy, hernia repair, and cholecystectomy)
• • History or presence of an abnormal ECG
• • History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias
• • History of alcoholism, drug abuse, or drug addiction
• • Use of any nicotine-containing or nicotine-replacement products within a specified timeframe prior to initiation of study treatment
• • Use of medications capable of inhibiting hepatic enzymes within a specified timeframe prior to initiation of study treatment
• • Participation in any other investigational drug study in which receipt of an investigational study drug occurred within a specified timeframe prior to initiation of study treatment
• • Use of any prescription medications/products including monoamine oxidase inhibitors, thioridazine, pimozide, or antidepressants within a specified timeframe prior to initiation of study treatment (2 weeks for antibiotics) (except hormone-replacement therapy or 2 weeks use of narcotics for pain)
• • Any vaccination or immunization within a specified timeframe prior to initiation of study treatment
• • Routine use of PPIs or histamine H2-receptor antagonists, or any use of these drugs within a specified timeframe prior to initiation of study treatment
• • Known hypersensitivity to ketoconazole or other azole antifungals
• • Use of any over-the-counter, nonprescription preparations (including supplements, vitamins, minerals, phytotherapeutic/herbal/plant-derived preparations, tryptophans, and St. John's wort) within a specified timeframe prior to initiation of study treatment
• • Use of alcohol-containing, grapefruit-containing, or caffeine-containing foods or beverages within a specified timeframe prior to initiation of study treatment
• • Donated blood within within a specified timeframe prior to initiation of study treatment
• • Received blood products within a specified timeframe prior to initiation of study treatment